Loading patent…
AssigneeCyclogenix Ltd
InventorsDuncan McGregor, William Eldridge, Simon Robins, Marie Fernie, Tricia White, Stuart Pritchard, Susan King
Estimating the term…
A modified igNAR peptide sequence derived from a wild-type igNAR peptide sequence is diversified by mutating the amino acid sequence at 50% or more of the amino acids in the CDR3 loop region and optionally at 50% or more of the amino acids in the CDR3 loop region. The modified igNAR peptide may have the sequence of SEQ ID NO: 8, 10 or 50 to 85. The modified igNAR peptides have binding activity against albumin protein sequences, such as human serum albumin. These modified igNAR peptides may have utility in extending the in vivo half-life of biological molecules e.g. therapeutic agents, and so may be used in medicine.
A modified immunoglobulin New Antigen Receptor (igNAR) peptide sequence derived from a wild-type igNAR peptide sequence, which is diversified by mutating the amino acid sequence at 50% or more of the amino acids in the CDR3 loop region, wherein the modified igNAR peptide sequence demonstrates a binding affinity for a target peptide sequence.
(canceled)
-27. (canceled)
A method of extending the in vivo or serum half-life of a therapeutic molecule by conjugating or associating the therapeutic molecule with a modified igNAR peptide sequence capable of binding to an albumin.
(canceled)
Dependencies are inferred from the claim text.